

Preclinical Study of a Novel BBB penetrant drug for Multiple Sclerosis

Daewoong Pharmaceutical



IMMUNOLOGY	Preclinical
Product Type	Small molecule
Indication	Multiple Sclerosis
Target	****
MoA(Mechanism of Action)	****
Competitiveness	<ol style="list-style-type: none"> 1. High BBB permeability 2. Dual mechanism of action in both the periphery and CNS 3. Potential for expansion to various neuroinflammatory diseases
Development Stage	Preclinical
Route of Administration	Oral administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.